1. Peripheral Blood Eosinophilia Has a Favorable Prognostic Impact on Transplant Outcomes after Allogeneic Peripheral Blood Stem Cell Transplantation 
Dong Hwan Kim, Gizelle Popradi, Wei Xu, Vikas Gupta, John Kuruvilla, Janice Wright, Hans A. Messner, Jeffrey H. Lipton 
Biology of Blood and Marrow Transplantation 
Volume 15, Issue 4, Pages (April 2009)
DOI: /j.bbmt
Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
The probability of development of early-onset eosinophlia (≥0.5 × 109/L) after allogeneic PBSC transplantation before day 100 (A) or the probability of development of late-onset eosinophlia occuring beyond day 100 (B).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
The plots of the overall survival, nonrelapse mortality, relapse incidence, and GVHD-specific survival of patients with and without the development of early-onset eosinophilia before day 100 (A-D) and of late-onset eosinophilia beyond day 100 (E-H).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

4. Figure 3
The plots of the overall survival, nonrelapse mortality, and relapse in patients with versus without the development of eosinophilia at the time of onset of overall chronic GVHD (A-C) and of extensive chronic GVHD (D-F).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

5. Figure 4
Serial change of absolute lymphocyte counts according to the development of late eosinophila after allogeneic transplantation.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

6. Figure 5
Semilandmark analysis for the overall survival, nonrelapse mortality, relapse, and GVHD-specific survival in patients with versus without the development of eosinophilia (A-E).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

7. Figure 6
Proposed mechanism of pathogenesis of cGVHD presenting with peripheral blood eosinophilia. This subtype of cGVHD is induced by the activation of Th2 cytokine pathway, which is shifted from Th1 activation pathway.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions